Vertex Pharmaceuticals Incorporated
Research & Development
11010 Torreyana Road
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
Vertex Pharmaceuticals is an Equal Opportunity Employer.
Key Contacts Media: email@example.com Investors: firstname.lastname@example.org Patient Inquiries: email@example.com
179 articles about Vertex Pharmaceuticals Incorporated
Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies
Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases
Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150
Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated.
Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation
Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in two Phase 3 studies in people with cystic fibrosis (CF).
Vertex Reports Third-Quarter 2018 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2018 and reviewed recent progress with its approved and investigational medicines.
Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that eight scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 32nd North American Cystic Fibrosis Conference taking place October 18-20, 2018 in Denver.
Vertex to Announce Third Quarter 2018 Financial Results on October 24
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close
Vertex to Present at the Morgan Stanley Healthcare Conference on September 14
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET.
Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines
Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines
Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations
Ludovic Fenaux to lead Vertex’s expanding International organization
Vertex Reports Second-Quarter 2018 Financial Results
Second-quarter 2018 total CF product revenues of $750 million, a 46% increase compared to $514 million in the second quarter of 2017
Vertex to Announce Second Quarter 2018 Financial Results on July 25
Vertex Pharmaceuticals Incorporated will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close.
Vertex Opens Expanded Research Site in San Diego
Vertex Pharmaceuticals Incorporated announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego.
Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF
Data from KALYDECO® (ivacaftor) studies show the potential to modify the long-term progression of the disease
Vertex to Present at the Goldman Sachs Healthcare Conference on June 13
Vertex Pharmaceuticals Incorporated announced that management will present at the Goldman Sachs Healthcare Conference
Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members
Vertex Pharmaceuticals Incorporated announced the recipients of scholarships as part of its second All in for CF Scholarship program.
Vertex Reports First-Quarter 2018 Financial Results
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.
Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated announced that it is initiating two Phase 3 studies of VX-445.
Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration
Q-State Biosciences, Inc. today announced that the company has entered into a strategic collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to discover drugs using Q-State’s novel Optopatch™ platform.
Fading Vertex Pharmaceuticals (CA) Drug Incivek was Also Fastest to Become a Blockbuster